Role of EPO on myocardial ischemic/reperfusion injury

• Grant number: 09/09583-3
• Support Opportunities: Regular Research Grants
• Start date: December 01, 2009
• End date: November 30, 2011
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: Orlando Petrucci Jr
• Grantee: Orlando Petrucci Jr
• Host Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

The low cardiac output syndrome is multifactorial, however the ischemic and reperfusion injury are inevitable during intra cardiac defects repair and it has important role on it. The identification of new myocardium protective strategies might reduce the incidence of low cardiac output syndrome with less mortality and morbidity. The erythropoietin (EPO) has direct cardioprotective effects in several in vivo and in vitro studies. We have not information in the literature of studies using a larger animals and immature myocardium. The main objective of this study is assessing the favorable EPO myocardium effects in clinically relevant ischemic/reperfusion model using neonatal piglets. This study is a prelude of future clinical studies. To test this hypothesis we will use sophisticated systolic and diastolic myocardium indexes. In addition, we will assess the RISK pathway activation and apoptosis results with EPO administration. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

SOUZA VILARINHO, KARLOS ALEXANDRE; MARTINS DE OLIVEIRA, PEDRO PAULO; ABDALLA SAAD, MARIO JOSE; EGHTESADY, PIROOZ; SILVEIRA FILHO, LINDEMBERG MOTA; VIEIRA, REINALDO WILSON; PETRUCCI, ORLANDO. Erythropoietin protects the systolic function of neonatal hearts against ischaemia/reperfusion injury. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, v. 43, n. 1, p. 156-162, JAN 2013. (09/09583-3)